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Conclusions. Normalization of hemoglobin does not lead toEffect of hemoglobin levels in hemodialysis patients with
regression of established concentric LV hypertrophy or LVasymptomatic cardiomyopathy.
dilation. It may, however, prevent the development of LVBackground. Hemoglobin levels below 10 g/dL lead to left
dilation, and it leads to improved quality of life.ventricular (LV) hypertrophy, LV dilation, a lower quality of
life, higher cardiac morbidity, and a higher mortality rate in
end-stage renal disease. The benefits and risks of normalizing
hemoglobin levels in hemodialysis patients without symptom- In 1836, Richard Bright observed that patients with
atic cardiac disease are unknown. end-stage renal disease had an anemic pallor during life,Methods. One hundred forty-six hemodialysis patients with
very high mortality rates, and left ventricular (LV) en-either concentric LV hypertrophy or LV dilation were randomly
largement at autopsy [1]. It has only recently becomeassigned to receive doses of epoetin a designed to achieve
hemoglobin levels of 10 or 13.5 g/dL. The study duration was apparent that these observations are interrelated. Death
48 weeks. The primary outcomes were the change in LV mass rates from cardiac disease are between 10 and 20 times
index in those with concentric LV hypertrophy and the change higher in dialysis patients than in the general population
in cavity volume index in those with LV dilation.
[2]. LV enlargement is present in approximately 80% ofResults. In patients with concentric LV hypertrophy, the
patients with end-stage renal disease and strongly pre-changes in LV mass index were similar in the normal and low
target hemoglobin groups. The changes in cavity volume index dicts the development of ischemic heart disease, cardiac
were similar in both targets in the LV dilation group. Treat- failure, and death, suggesting that it is maladaptive [3–5].
ment-received analysis of the concentric LV hypertrophy group Two major types of LV enlargement may occur in re-
showed no correlation between the change in mass index and sponse to chronic hemodynamic stress. In pressure over-a correlation between the change in LV volume index and mean
load, thickening of the LV walls allows the generationhemoglobin level achieved (8 mL/m2 per 1 g/dL hemoglobin
of greater intraventricular pressure, thus overcoming thedecrement, P 5 0.009). Mean hemoglobin levels and the
changes in LV mass and cavity volume index were not corre- outflow impediment. This concentric LV hypertrophy is
lated in patients with LV dilation. Normalization of hemoglo- accompanied by normal chamber volume. In chronic
bin led to improvements in fatigue (P 5 0.009), depression volume overload, lengthening of cardiac myofibrils and
(P 5 0.02), and relationships (P 5 0.004). LV dilation lead to an increased cardiac stroke volume
by the Starling mechanism. Both types of LV enlarge-
ment are common in end-stage renal disease. LV massKey words: epoetin a, progressive renal disease, end-stage renal dis-
is prognostically dominant in concentric LV hypertro-ease, ischemic heart disease, ventricular enlargement, chronic hemody-
namic stress. phy. In contrast, cavity size predicts outcome in patients
with LV dilation [6]. The characteristic evolution of LVReceived for publication December 16, 1999
morphology in dialysis patients is progressive dilationand in revised form March 6, 2000
Accepted for publication April 5, 2000 with associated LV hypertrophy, which is associated with
anemia [7].Ó 2000 by the International Society of Nephrology
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Table 1. Baseline characteristics of hemodialysis patients with concentric left ventricular (LV) hypertrophy or LV dilation randomly allocated
to either partial correction of anemia or normalization of hemoglobin with epoetin a
Target hemoglobin
Concentric LV hypertrophy LV dilation
9.5–10.5 g/dL 13.0–14.0 g/dL 9.5–10.5 g/dL 13.0–14.0 g/dL
Number 36 34 37 39
Age years 60 (56,65) 62 (57,67) 62 (57,67) 62 (58,66)
Male 16 (44%) 16 (47%) 28 (76%) 31 (79%)
Caucasian 24 (67%) 25 (74%) 28 (76%) 31 (79%)
Renal disease
Glomerulonephritis 11 (31%) 9 (26%) 10 (27%) 11 (28%)
Diabetes mellitus 11 (31%) 9 (26%) 9 (24%) 14 (36%)
Renovascular 5 (14%) 7 (21%) 8 (22%) 7 (18%)
Other 9 (25%) 9 (26%) 10 (27%) 7 (18%)
Body surface area m2 1.73 (1.66,1.80) 1.75 (1.67,1.83) 1.79 (1.72,1.85) 1.82 (1.75,1.90)
Duration of dialysis therapy years 5.6 (3.7,7.5) 5.6 (3.7,7.5) 3.7 (2.4, 5.0) 3.3 (2.2, 4.4)
Dialysis time hours/week 11.3 (10.9,11.6) 11.2 (10.5, 11.8) 11.4 (10.8, 12.0) 11.6 (11.1,12.1)
Kt/V 1.47 (1.36,1.59) 1.45 (1.34,1.56) 1.51 (1.36,1.66) 1.44 (1.34,1.53)
Vascular access
Natural fistula 25 (69%) 22 (65%) 32 (86%) 32 (82%)
Graft 10 (28%) 8 (24%) 2 (5%) 3 (8%)
Catheter 1 (3%) 3 (9%)a 3 (8%) 4 (10%)
LV mass index g/m2 139 (132,149) 147 (138, 156) 165 (149,182) 172 (161,184)
LV cavity volume index mL/m2 69 (63,75) 63 (57,69) 123 (113,133) 122 (113,132)
Figures in parentheses represent 95% confidence intervals.
a Type of access was not specified in 1 patient
Partial correction of the anemia of renal failure, with low (9.5 to 10.5 g/dL) target hemoglobin levels on LV
mass index in patients with echocardiographic concentricepoetin a, improves quality of life, exercise capacity,
cognitive function [8–13], and ameliorates LV hypertro- LV hypertrophy, defined as LV hypertrophy with normal
cavity volume. The second was to compare the effect ofphy [14, 15]. It is not surprising, therefore, that hemoglo-
bin target levels have become a matter of considerable these hemoglobin targets on LV cavity volume index in
patients with LV dilation. The secondary comparisonsinterest, and that the potential risks and benefits of full
correction of renal anemia are being examined using included changes in the LV cavity volume index in pa-
tients with concentric LV hypertrophy and LV mass in-randomized, controlled clinical trials. A large trial com-
paring a normal to a conventionally low hematocrit in dex in patients with LV dilation. Changes in quality
of life were also examined, as were the comparativehemodialysis patients with clinical evidence of congestive
heart failure or ischemic heart disease showed an in- incidence of arteriovenous access thrombosis, cardiac
events, and death.crease in vascular access loss and shorter survival in the
high hematocrit group. This difference in mortality was
Patientsno longer statistically significant when multiple interim
analyses were taken into account [16]. In our trial, we Inclusion criteria included: (1) age greater than 17
years; (2) maintenance hemodialysis for greater thanreport on the effects of a normal hemoglobin target in
hemodialysis patients who are at an earlier phase of three months; (3) LV hypertrophy (LV mass indexed to
a body surface area of greater than 131 g/m2 in malestheir cardiac disease, those with cardiomyopathy without
clinical symptoms of cardiac disease. Two types of pa- and 100 g/m2 in females [17] or LV dilation (defined as
LV cavity volume indexed to a body surface area oftients were studied: those with concentric LV hypertro-
greater than 90 mL/m2 [18]; (4) a hemoglobin concentra-phy (LV hypertrophy and normal cavity volume) and
tion between 9 and 11 g/dL in the month prior to random-those with LV dilation.
ization; (5) stable vascular access for the previous three
months; and (6) life expectancy greater than 18 months.
METHODS
Exclusion criteria included: (1) angina pectoris, myocar-
Objectives dial infarction, coronary artery bypass surgery, percuta-
neous transluminal angioplasty or congestive heart fail-This was a 48-week, open-label, randomized, con-
trolled trial in maintenance hemodialysis patients with- ure within the previous 12 months; (2) active bleeding;
(3) uncorrected iron deficiency; (4) valvular heart diseaseout symptomatic ischemic heart disease or cardiac fail-
ure. The study had two coprimary objectives. The first for which surgical intervention was planned within one
year; and (5) intravenous iron dextran intolerance.was to compare the effect of normal (13 to 14 g/dL) and
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Table 2. Clinical characteristics of hemodialysis patients with concentric LV hypertrophy or LV dilation randomly allocated to either partial
correction of anemia or normalization of hemoglobin with epoetin a during the 48 weeks of the trial
Target hemoglobin
Concentric LV hypertrophy LV dilation
9.5–10.5 g/dL 13.0–14.0 g/dL 9.5–10.5 g/dL 13.0–14.0 g/dL
Number 36 34 36 36
Hemoglobin g/dL 10.4 (10.2,10.6) 12.2 (11.9,12.5) 10.4 (10.2,10.6) 12.3 (12.0,12.5)
P,0.001 P,0.001
Epoetin dose U/week 8993 (6861,11124) 19058 (14163,23953) 8092 (6762,9422) 21049 (16686,25412)
P,0.001 P,0.001
Epoetin dose U/kg/week 139 (102,176) 293 (208,377) 120 (97,144) 283 (229,337)
P,0.001 P,0.001
Iron dextran mg/week 44 (29,58) 64 (43,85) 46 (34,58) 68 (51,84)
P50.1 P50.04
Systolic blood pressure mm Hg 157 (153,161) 162 (157,166) 155 (150,160) 154 (148,160)
P50.1 P50.3
Diastolic blood pressure mm Hg 81 (78,84) 82 (79,84) 82 (79,85) 84 (81,87)
P50.7 P50.3
Number of antihypertensive medications per patient 1.2 (0.9,1.4) 2.0 (1.6,2.4) 1.5 (0.8,2.1) 1.5 (1.1,1.9)
P50.001 P50.9
Kt/V 1.51 (1.40,1.61) 1.44 (91.36,1.52) 1.50 (1.40,1.61) 1.39 (1.32,1.45)
P50.3 P50.02
Data are presented as means with 95% confidence intervals in parentheses. Hemoglobin and blood pressure levels were measured pre-dialysis.
Interventions at the coordinating center in St. John’s met weekly to
review each patient’s hemoglobin level, epoetin dose,Patients were randomly assigned to a target hemoglo-
iron saturation, and blood pressure level. Treatment rec-bin level of 9.5 to 10.5 g/dL or 13 to 14 g/dL. Patients
ommendations regarding epoetin a dose, intravenouswere stratified by their baseline LV morphology (concen-
iron dextran administration, and blood pressure controltric LV hypertrophy or LV dilation) and by study site.
were made based on these data and were faxed to theEpoetin a was administered subcutaneously in all pa-
participating centers.tients. In those assigned to a normal hemoglobin target,
a ramping phase of up to 24 weeks was followed by a
Measurements24-week maintenance phase. Ramping was performed
Echocardiography was carried out on the day after aby increasing the prestudy epoetin a dose by 50% and
hemodialysis session, with the patients within 1 kg ofthen by an extra 25% if the change in hemoglobin was
dry weight. Echocardiography was performed blind toless than 0.5 g/dL in two weeks. Dose reduction was
the patient treatment group assignment. The Americanmandated by a change of hemoglobin concentration of
Society of Echocardiography method was employed, us-greater than 1.0 g/dL over two weeks. Apart from these
ing leading-edge to leading-edge measurements for theinitial dose increments in the high hemoglobin target
septum and posterior wall and the LV internal dimensiongroup, dosing guidelines were similar in the high- and
taken at the Q wave of the electrocardiogram [20]. LVlow-target hemoglobin groups. When the hemoglobin
mass, in grams, was calculated as 0.00083 · [(LV end-level was below target levels, the epoetin dose was in-
diastolic diameter mm 1 interventricular septum thick-creased by 25%; when the hemoglobin was above target
nesss mm 1 posterior wall thickness mm)3 2 (LV end-levels, the epoetin dose was decreased by 25%.
diastolic diameter mm)3 1 0.6 [21]. LV cavity volume
Monitoring was calculated as 0.001047 · (LV end-diastolic diameter
mm)3 [22]. Repeat echocardiography was scheduled atPredialysis hemoglobin and blood pressure levels were
48 weeks, or earlier, when patients exited the study.measured every week for 24 weeks and every 2 weeks
Follow-up studies were arbitrarily defined as being validthereafter. Transferrin saturation was measured every 2
for efficacy analysis if they were performed after 40weeks for 24 weeks and every 4 weeks thereafter. Serum
weeks, based on the belief that this duration would bechemistry, including Kt/V, was measured monthly. Kt/V
needed to show differences in LV morphology relatedis a unitless measure of dialysis adequacy in which K is
to differential change in hemoglobin levels.the rate of urea clearance by dialysis, t is the time spent
Quality of life was assessed using one instrument thaton dialysis, and V the patient’s volume of urea distribu-
has been validated in dialysis patients, the Kidney Dis-tion. Currently, a Kt/V value above 1.2 is recommended
[19]. A study monitoring group (R.N.F., P.S.P., and J.M.) ease Questionnaire, and two generic instruments, the
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Fig. 1. Weekly hemoglobin levels (A) and
epoetin a doses (B) in patients with concentric
left ventricular (LV) hypertrophy. Symbols
are: (s) mean hemoglobin levels in the low
hemoglobin target group; (d) normal hemo-
globin target group. The vertical bars are 95%
confidence intervals.
36-item Medical Outcomes Study Short Form Survey, the Health Utilities Index had not been validated outside
these languages. We initially planned to measure thesecommonly known as SF-36, and the Health Utilities In-
dex. The Kidney Disease Questionnaire contains 26 at baseline and at 12, 24, and 48 weeks. Because of
logistic difficulties, it was decided to allow individualquestions, leading to scores in five dimensions: fatigue,
depression, relationships with others, frustration, and investigators and patients to omit the week 12 Kidney
Disease Questionnaire at their discretion. At the end ofphysical symptoms, with the last dimension being patient
the study, only half of patients enrolled had this mea-specific. All dimensions are scored on a Likert scale
sured at 12 weeks. Among these patients, there were nobetween seven (no problem) and one (a severe problem)
differences between the high- and low-target groups.[8, 23]. The SF-36 evaluates eight health-related aspects:
These data are not presented in detail in this report.physical function, social function, physical role, emo-
tional role, mental health, energy, pain, and general
Sample sizehealth perception. Scores can range between 0 (worst
possible) and 100 (best possible) for all eight dimensions A previous prospective inception cohort study of dial-
ysis patients showed that the LV mass index was of[24]. The Health Utilities Index provides an overall index
of health, derived from scores in seven aspects: sensation, greater prognostic value in those with a LV cavity vol-
ume #90 mL/m2. In contrast, the LV cavity volume indexmobility, emotion, cognition, self-care, pain, and fertility.
This is an interval scale that can vary in theory between had more prognostic value than mass index in patients
with a LV cavity volume index .90 mL/m2. Also, anemia0 (death) and 1 (perfect health) [25]. Quality of life was
not assessed in subjects who did not speak English or was more strongly associated with LV dilation than with
concentric LV hypertrophy. In addition, this study en-French because the Kidney Disease Questionnaire and
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Fig. 2. Weekly hemoglobin levels (A) and
epoetin a doses (B) in patients with LV dila-
tion. Symbols are: (s) mean hemoglobin lev-
els in the low hemoglobin target group; (d)
normal hemoglobin target group. The vertical
bars are 95% confidence intervals.
abled an estimation of the variance in the change of LV Analysis
parameters over a one year period [6]. Based on the Echocardiographic outcomes were compared sepa-
hypothesis that the respective LV response to normaliz- rately in patients with concentric LV hypertrophy and
ing hemoglobin might differ, it was decided to determine LV dilation, based on the a priori hypothesis that re-
sample size separately in patients with concentric LV sponse to hemoglobin targets would differ in these two
hypertrophy and LV dilation. In both groups, two-tailed groups [6]. In contrast, quality of life and safety outcomes
hypotheses were used with the a set at 0.05, b set at were analyzed for the combined group because there was
0.20, and a 48-week dropout rate estimated at 12.5%. no a priori hypothesis that these would differ according
For patients with concentric LV hypertrophy, a sample to LV morphology. Analysis of variance was used when
size of 70 patients was needed to detect a difference in parametric distributional assumptions were met. Repeated-
LV mass index of 27 g/m2 between baseline and 48 weeks measures analysis of variance was used in the analysis
(a 20% improvement with an associated reduction in of quality of life parameters measured at baseline and at
mortality after 2 years of 20%), assuming that the stan- 24 and 48 weeks. When interval data were not normally
dard deviation of change in mass index of 37 g/m2. For distributed, we used the Mann–Whitney U-test for the
patients with LV dilation, a sample size of 70 patients comparison of central tendency and the Kolmogorov–
was needed [6] to detect a difference in a cavity volume Smirnov Z-test to compare distributional shape. Chi-
index of 24 mL/m2 (a 20% improvement with an associ- squared analysis or Fisher’s Exact test was used to com-
ated reduction in mortality after 2 years of 50%), assum- pare categorical variables. Correlation-regression analy-
ing that the standard deviation of change in the cavity sis was used to test the association between changes in
LV mass and volume and achieved hemoglobin levels.volume index was 31 mL/m2.
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Fig. 3. (A) Patients with concentric LV hy-
pertrophy. Cumulative frequency distribution
of the change in LV mass index from baseline
to 48 weeks in the low (solid lines) and high
(dotted lines) target hemoglobin groups. The
groups are similar in terms of central tendency
(P 5 0.35 by Mann–Whitney U-test) and dis-
tribution shape (P 5 0.60 by the Kolmogorov–
Smirnov Z-test). (B) Patients with concentric
LV hypertrophy. Change in LV mass index
from baseline to 48 weeks on the Y axis plotted
against mean hemoglobin levels achieved.
Symbols are: (s) mean hemoglobin levels in
the low hemoglobin target group; (d) normal
hemoglobin target group. The correlation be-
tween the change in LV mass index and mean
hemoglobin did not reach statistical signifi-
cance (b coefficient 26.94 g/m2 per 1 g/dL
increment in mean hemoglobin, 95% confi-
dence interval 214.61 to 7.30 g/m2 per 1 g/dL,
R 5 0.24, P 5 0.075).
The potential impact of dropouts was assessed by assum- the median time to reach the target range was 14.5 weeks.
ing a scenario of no change from baseline. The mean hemoglobin during the 48 weeks of the study
was 1.8 g/dL higher, and the mean epoetin dose was
10,065 units higher in the normal hemoglobin group.
RESULTS Figure 1 shows these differences over time. Although
Patient characteristics intravenous iron dextran use and systolic blood pressure
levels tended to be higher and Kt/V lower in the normalA total of 146 patients entered the study between May
hemoglobin group, these differences did not reach statis-4, 1995, and December 20, 1996. Seventy patients had
tical significance. Patients in the high target group re-concentric LV hypertrophy, and 76 patients had LV dila-
ceived significantly more antihypertensives per patient,tion. The baseline characteristics of patients with concen-
2.0, during the study, compared with 1.2 in the low target.tric LV hypertrophy and LV dilation are shown in Table 1.
Calcium channel anatagonist (P 5 0.026), vasodilator (P 5In patients with concentric LV hypertrophy, the mean
0.028), and centrally active agent use (P 5 0.017) werebaseline LV mass indices were 139 versus 147 g/m2, while
higher in the normal hemoglobin group, while b blocker,the mean baseline cavity volume indices were 69 versus
angiotensin-converting enzyme inhibitor and a blocker63 mL/m2, respectively, in the low- and high-target hemo-
use were similar.globin groups. For patients with LV dilation, the corre-
The characteristics of LV dilation patients during thesponding figures were 165 versus 172 g/m2 for LV mass
study are shown in Table 2. Among patients assigned toindex and 123 versus 122 mL/m2 for cavity volume index.
a normal hemoglobin target, the median time to reachThere were no statistically significant differences in any
the target range was 14 weeks. The mean hemoglobinof these parameters according to assigned target hemo-
was 1.9 g/dL higher, and the mean epoetin dose wasglobin level in either condition.
12,957 units higher in the normal hemoglobin group.
Clinical effects of the intervention Figure 2 shows these differences over time. Intravenous
iron dextran use was higher and Kt/V lower in the normalThe clinical characteristics of concentric LV hypertro-
hemoglobin target, with both differences achieving sta-phy patients during the study are shown in Table 2.
Among patients assigned to a normal hemoglobin target, tistical significance. Systolic blood pressure, diastolic
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Fig. 4. (A) Patients with concentric LV hy-
pertrophy. Cumulative frequency distribution
of the change in LV cavity volume index from
baseline to 48 weeks in the low (solid lines)
and high (dotted lines) target hemoglobin
groups. The groups are similar in terms of
central tendency (P 5 0.13 by the Mann–
Whitney U-test) but differ in terms of distribu-
tion shape (P 5 0.036 by the Kolmogorov–
Smirnov Z-test). (B) Patients with concentric
LV hypertrophy. Change in LV cavity volume
index from baseline to 48 weeks on the Y
axis plotted against mean hemoglobin levels
achieved. Symbols are: mean hemoglobin lev-
els in the low hemoglobin target group; (d)
normal hemoglobin target group. The correla-
tion between change in LV cavity volume in-
dex and mean hemoglobin was statistically sig-
nificant (b coefficient 28.00 mL/m2 per 1 g/dL
increment in mean hemoglobin, 95% confi-
dence interval 213.91 to 22.09 mL/m2 per 1
g/dL, R 5 0.34, P 5 0.009).
blood pressure, and the number and types of antihyper- the low hemoglobin group than in the normal hemoglo-
tensive agents used were similar in both target groups. bin group (P 5 0.036). The change in cavity volume was
inversely correlated with the mean hemoglobin level,
Echocardiographic outcomes such that each 1 g/dL fall in hemoglobin was associated
Concentric LV hypertrophy group. Fifty-eight (83%) with an increase in volume index of 8 mL/m2 (P 5 0.009;
patients had a repeat echocardiogram after 40 weeks. Fig. 4B).
Follow-up studies were unavailable in 12 patients, 5 in All conclusions about echocardiographic outcomes
the low target and 7 in the high target group. The reasons were identical when a no-change scenario was assumed
included transplantation (N 5 3), death (N 5 3), with- for the 12 patients without valid week 48 echocardio-
drawal of consent (N 5 3), ischemic heart disease (N 5 1), grams. Similarly, conclusions regarding associations be-
and other causes (N 5 1) before 40 weeks and because tween echocardiographic outcomes and hemoglobin lev-
of the failure to perform a follow-up study in one patient.
els were identical in multiple regression models that
The mean change in body surface area was zero in
included serial blood pressure levels, epoetin dose, theboth hemoglobin target groups (P 5 0.84). The changes
number and class of antihypertensive agents, and indicesin mass index, the primary outcome measure, were simi-
of dialysis adequacy.lar in both target groups (Fig. 3A). The correlation be-
LV dilation group. Sixty-three (83%) LV dilation pa-tween mean hemoglobin achieved and the change in
tients had a repeat echocardiogram after 40 weeks. Fol-mass index approached statistical significance (P 5 0.075;
low-up studies were unavailable in 13 patients: 7 in theFig. 3B).
low target and 6 in the normal target group. The reasonsThe changes in LV volume index are shown in Figure
included death (N 5 5), withdrawal of consent (N 5 2),4A. Measures of the central tendency were similar in
transplantation (N 5 2), ischemic heart disease (N 5 1),both groups (P 5 0.13). Distribution shape differed, sug-
gesting a greater tendency to progressive LV dilation in cancer (N 5 1), arteriovenous access problems (N 5 1), and
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Fig. 5. (A) Patients with LV dilation. Cumu-
lative frequency distribution of the change in
LV mass index from baseline to 48 weeks in
the low (solid lines) and high (dotted lines)
target groups. The groups are similar in terms
of central tendency (P 5 0.66 by Mann–
Whitney U-test) and distribution shape (P 5
0.93 by the Kolmogorov–Smirnov Z-test). (B)
Patients with LV dilation. Change in LV mass
index from baseline to 48 weeks on the Y
axis plotted against mean hemoglobin levels
achieved. Symbols are: (s) mean hemoglobin
levels in the low hemoglobin target group;
(d) represent the normal hemoglobin target
group. The correlation between the change in
LV mass index and mean hemoglobin was not
statistically significant (b coefficient 0.03 g/m2
per 1 g/dL increment in mean hemoglobin,
95% confidence interval 20.90 to 0.85 g/m2
per 1 g/dL, R 5 0.01, P 5 0.95).
other causes (N 5 1). The mean change in body surface with others (P 5 0.004) in the normal-hemoglobin group,
while physical symptoms and frustration were similar inarea was zero in both hemoglobin target groups (P 5 0.89).
The changes in LV mass and cavity volume index are both groups. The fatigue, depression, and relationships
scores were most divergent at 24 weeks and tended toillustrated in Figures 5 and 6. The changes in LV mass
and cavity volume index were similar in both groups, converge thereafter. The mean Health Utilities Index
was 0.81 (95% confidence interval 0.78, 0.85). For theand there was no correlation between mean hemoglobin
level and the observed echocardiographic changes. SF-36 instrument, the mean scores were 47 (43, 50) for
general health, 75 (72, 79) for mental health, 69 (65, 74)All conclusions regarding echocardiographic out-
comes were identical when a no-change scenario was for bodily pain, 55 (50, 60) for physical function, 77 (71,
83) for emotional role, 71 (66, 76) for social function,assumed for the 13 dropouts. Similarly, conclusions re-
garding associations between echocardiographic out- and 50 (45, 53) for vitality. The Health Utilities Index
and all dimensions of the SF-36 instrument remainedcomes and hemoglobin levels were identical in multiple
regression models that included serial blood pressure unchanged over time. There were no clinically important
or statistically important differences between scores ac-levels, epoetin dose, the number and class of antihyper-
tensive agents and indices of dialysis adequacy. cording to hemoglobin group at any time point.
All conclusions regarding quality of life parameters
Quality of life outcomes were identical when a no-change scenario was assumed
for patients with missing data at weeks 24 or 48.Quality of life scores using the Kidney Disease Ques-
tionnaire are shown in Table 3. The baseline scores in
Vascular eventsall five dimensions were similar in the low- and normal-
hemoglobin groups. Using repeated-measures analysis The incidence of arteriovenous access thrombosis, car-
diac events, and death was similar in both hemoglobinof variance, there were greater improvements in fatigue
(P 5 0.009), depression (P 5 0.02), and relationships groups (Table 4).
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Fig. 6. (A) Patients with LV dilation. Cumu-
lative frequency distribution of the change in
LV cavity volume index from baseline to 48
weeks in the low (solid lines) and high (dotted
lines) target hemoglobin groups. The groups
are similar in terms of central tendency (P 5
0.45 by the Mann–Whitney U-test) and distri-
bution shape (P 5 0.26 by the Kolmogorov–
Smirnov Z-test). (B) Patients with LV dila-
tion. Change in LV cavity volume index from
baseline to 48 weeks on the Y axis plotted
against mean hemoglobin levels achieved on
the X axis. Symbols are: (s) mean hemoglobin
levels in the low hemoglobin target group; (d)
normal hemoglobin target group. The correla-
tion between change in LV cavity volume in-
dex and mean hemoglobin is not statistically
significant (b coefficient 0.46 mL/m2 per 1 g/dL
increment in mean hemoglobin, 95% confi-
dence interval 20.31 to 1.24 mL/m2 per 1 g/dL,
R 5 0.02, P 5 0.24).
DISCUSSION normalization of hematocrit trial recently reported by
Besarab et al, patients in the higher hematocrit groupCardiac morbidity and mortality in dialysis patients
had a higher rate of vascular access thrombosis and ausually results from cardiomyopathy or ischemic heart
trend toward greater mortality than those in the lowdisease or a combination of these disorders. Progressive
hematocrit target [16]. The current study focused onLV dilation with compensatory hypertrophy appears to
hemodialysis patients at an earlier phase of cardiac dis-be the characteristic evolution of cardiomyopathy in dial-
ease when cardiomyopathy was present but not yet at aysis patients [7]. With progressive death of myocytes,
symptomatic level. The study was primarily designed toconcentric LV hypertrophy may ultimately evolve into
compare the impact of partial and complete normaliza-LV dilation. Cardiomyopathy, whether it be concentric
tion on LV mass index in those with concentric LV hy-LV hypertrophy or LV dilation, predisposes to heart
pertrophy and on LV volume index in those with LVfailure and symptomatic ischemic heart disease in dialysis
dilation. Clearly, the study showed no differences be-patients [5]. These conditions, in turn, predispose to ear-
tween partial and full normalization of hemoglobin inlier death [4–6]. Anemia is an independent risk factor
terms of these coprimary outcomes. It is possible thatfor LV dilation, LV hypertrophy, and death in patients
the study duration of 48 weeks may be too short to rulewith end-stage renal disease [26–29].
out later effects on outcome comparisons.Partial correction of anemia with epoetin improves
Patients with concentric LV hypertrophy, a conditionquality of life and partly ameliorates LV dilation and
characterized by increased wall thickness and normalhypertrophy [8–15]. Normalization of hematocrit, with
LV volumes, did not have regression of hypertrophyepoetin, in hemodialysis patients in the later phases of
because of normalization of hemoglobin, although atheir cardiac disease (when they are symptomatic with
trend in this direction was observed. However, they ap-either ischemic heart disease or cardiac failure) does
not appear to improve outcome. In the United States peared less likely than control patients to have progres-
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Table 3. Quality of life scores, using the Kidney Disease Questionnaire, before and after partial correction compared to normalization of
hemoglobin with epoetin a, in hemodialysis patients with asymptomatic cardiomyopathy
Change from Change from
Baseline baseline to week 24 baseline to week 48 P a for trend
Target hemoglobin
9.5–10.5 g/dL N554 N548 N545
13–14 g/dL N560 N551 N549
Fatigue
9.5–10.5 g/dL 4.53 (4.15,4.91) 20.04 (20.22,0.14) 20.01 (20.30,0.29)
13–14 g/dL 4.41 (4.10,4.73) 0.46 (0.17,0.75) 0.25 (20.05,0.55) 0.009
P50.63 P50.004 P50.22
Depression
9.5–10.5 g/dL 5.20 (4.81,5.59) 0.00 (20.23,0.24) 0.20 (20.11,0.51)
13–14 g/dL 5.02 (4.69,5.35) 0.30 (0.06,0.53) 0.05 (20.28,0.37) 0.022
P50.47 P50.083 P50.49
Relationships
9.5–10.5 g/dL 4.96 (4.49,5.32) 20.04 (20.31,0.23) 0.20 (20.15,0.46)
13–14 g/dL 5.04 (4.78,5.29) 0.31 (0.15,0.48) 20.07 (20.38,0.24) 0.004
P50.71 P50.025 P50.31
Physical symptoms
9.5–10.5 g/dL 3.68 (3.28,4.08) 0.71 (0.38,1.04) 1.17 (0.76,1.57)
13–14 g/dL 3.49 (3.17,3.81) 0.79 (0.39,1.20) 1.10 (0.55,1.64) 0.82
P50.45 P50.76 P50.84
Frustration
9.5–10.5 g/dL 5.07 (4.66,5.08) 20.01 (20.31,0.27) 0.15 (20.15,0.46)
13–14 g/dL 4.93 (4.57,5.30) 0.16 (20.08,0.39) 20.07 (20.38,0.24) 0.36
P50.63 P50.36 P50.31
Using repeated measures ANOVA.
Table 4. Major vascular events following partial correction of with a better prognosis for their arteriovenous access.
anemia compared to normalization of hemoglobin with epoetin
The event rates were small, and our study did not havea, in hemodialysis patients with asymptomatic cardiomyopathy
enough statistical power to exclude a moderate impact
Target hemoglobin of hemoglobin normalization on access loss. The larger
9.5–10.5 g/dL 13–14 g/dL study of Besarab et al revealed a highly significant in-
N573 N573 P a
crease in vascular access loss in patients in whom hemato-
Arteriovenous access thrombosis 10 (14%) 6 (8%) 0.4 crit was normalized [16]. The proportion using naturalCardiac eventb 10 (14%) 10 (14%) 0.6
fistulae was 23% in the latter study, in contrast to a figureDeath 3 (4%) 4 (5%) 1.0
of 76% in our study.a Fisher’s exact test
b Angina pectoris, myocardial infarction, pulmonary edema or cardiac failure The impact of normalization of hemoglobin on blood
pressure was of interest. Blood pressures and use of
antihypertensives were similar in LV dilation patients
allocated to either hemoglobin target. In contrast, nor-sive LV dilation. Normalization of hemoglobin had no
malization of hemoglobin was associated with a tendencybeneficial echocardiographic effects in patients with
to higher systolic blood pressure and a clear need forovert LV dilation. It should be noted that the extent of
more intensive antihypertensive therapy in concentricLV dilation in this group was severe, with a mean LV
hypertrophy patients. It is conceivable that normaliza-cavity volume index at baseline of 123 mL/m2. The cur-
tion of hemoglobin may further increase peripheral vas-rent study suggests that normalization of hemoglobin at
cular resistance [30], and that a modest rise in bloodan earlier phase may be beneficial by preventing LV
pressure could blunt the impact of normalization of he-dilation. Further studies in predialysis patients or in pa-
moglobin on LV hypertrophy. In addition, epoetin itselftients starting dialysis therapy are necessary to determine
has a direct impact on endothelin production, which maywhether normalization of hemoglobin can prevent the
explain a tendency toward higher blood pressures [31].development of cardiac disease.
The dose of epoetin a prescribed was 2.4 times greaterQuality of life was improved by the normalization of
in the intervention group than in the control group, whilehemoglobin. We found no differences in the incidence
the intravenous dose of iron dextran was 1.5 times higher.of arteriovenous access thrombosis between the two he-
The dose of epoetin doses used in the intervention groupmoglobin target groups. The rates of access loss were
appeared to be lower than in the study of Besarab et al,low and similar in both target hemoglobin groups. Pa-
which may reflect the fact that subcutaneous administra-tients with ongoing access problems were specifically
excluded in the study design. Clearly, we selected a group tion was used in the former and intravenous administra-
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N, Stein RA, Friedman EA: Exercise in hemodialysis patientstion in the latter studies [16]. Kt/V was lower in the
after treatment with recombinant human erythropoietin. Nephron
normal-hemoglobin group. The clinical consequences of 58:315–319, 1991
what appears to be a modest reduction in Kt/V are un- 13. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei
U: Improved physical performance after treatment of renal anemiaknown, but should be clarified by the ongoing HEMO
with recombinant human erythropoietin. Nephron 58:129–134,trial. 1991
Cardiac disease appears to be rapidly progressive in 14. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jac-
quot C, Safar M, Drueke TB: Vascular changes in hemodialysisend-stage renal disease. The findings of this study suggest
patients in response to recombinant human erythropoietin. Kidneythat normalization of hemoglobin does not induce re- Int 36:878–882, 1989
gression of overt LV dilation or concentric LV hypertro- 15. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies
ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-termphy. However, enhancement of quality of life and pre-
cardiorespiratory effects of amelioration of renal anaemia by eryth-vention of LV dilation may be attractive for many ropoietin. Lancet 335:489–493, 1990
patients, despite an increased need for antihypertensives, 16. Besarab A, Kline Bolton W, Browne JK, Egrie JC, Nissenson
AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects ofepoetin a and iron dextran, and a somewhat lower deliv-
normal as compared with low hematocrit in patients with cardiacered dialysis dose. The study suggests that a subgroup of disease who are receiving hemodialysis and epoetin. N Engl J Med
end-stage renal disease patients may benefit from higher 339:584–590, 1998
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